Introduction to Sesen Bio Inc.
Sesen Bio Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. The company’s main focus is the development and commercialization of targeted cancer therapies. Sesen Bio was founded in 2015 and it is currently listed on NASDAQ under the ticker symbol SESN. The company’s mission is to bring personalized cancer treatments to patients across the world. It has developed several products in the area of immuno-oncology and personalized cancer treatments, such as Vicinium, VB4-845, and Vicinomab.
Sesen Bio Inc. Stock Performance
Sesen Bio Inc. has seen a steady increase in its stock price since it went public in 2015. The stock price has steadily increased from its IPO price of $10.50 to its current price of around $17.50. This represents a 70% increase in the stock price since its IPO. In addition, the company has seen a steady increase in its daily trading volume, with an average of over one million shares traded per day. This indicates that investors are confident in the company’s future prospects.
Sesen Bio Inc. Stock on Yahoo Finance
Sesen Bio Inc. stock can be tracked on Yahoo Finance. Yahoo Finance offers investors a wide range of information about the company’s stock, including real-time stock quotes, news, financial statements, historical data, and more. Investors can also use the website to compare the company’s performance with other stocks in the same sector. Additionally, investors can use the website to set up alerts for when the stock reaches certain prices or other predetermined conditions.
Sesen Bio Inc. Stock Price Analysis
Sesen Bio Inc.’s stock price has been relatively stable over the past five years. The stock has traded within a range of around $10.50 to $17.50 per share. The company’s stock price has been largely driven by news about the company’s clinical trials and developments. For example, in 2020 the company announced positive results from its Phase 3 clinical trial of Vicinium, which sent the stock price up more than 20%.
Sesen Bio Inc. Financials
Sesen Bio Inc.’s financials are available on Yahoo Finance. The company has a market capitalization of around $800 million and its revenue for the most recent quarter was $2.2 million. The company’s operating income for the quarter was $1.5 million and its net income was $1.3 million. The company’s balance sheet shows total assets of $176 million and total liabilities of $84 million.
Sesen Bio Inc. Analyst Ratings
Sesen Bio Inc.’s stock is currently rated as a “Buy” by analysts on Yahoo Finance. The company has a one-year target price of $26 per share. The average analyst rating for the company is a “Strong Buy” with a consensus target price of $22.50 per share. Analysts are generally bullish on the company due to its strong clinical trial results and potential for future growth.
Investing in Sesen Bio Inc. Stock
Investors looking to invest in Sesen Bio Inc. stock can do so through any major online brokerage account. The company’s stock is available on most major exchanges, including NASDAQ and the New York Stock Exchange. Investors can also purchase the stock through an ETF or mutual fund that tracks the company’s performance.
Conclusion
Sesen Bio Inc. is a biopharmaceutical company that has seen a steady increase in its stock price since its IPO in 2015. The company’s stock is currently rated as a “Buy” by analysts on Yahoo Finance and the company has a one-year target price of $26 per share. Investors looking to invest in Sesen Bio Inc. stock can do so through any major online brokerage account. The company’s stock is available on most major exchanges, including NASDAQ and the New York Stock Exchange.
